Targeted inhibition of Nrf2 potentiates antitumor immunity and enhances the efficacy of immunotherapy in hepatocellular carcinoma
Open Access
- 24 March 2026
- journal article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (3) , e010841
Abstract
Background: Immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T-cell (CAR-T) immunotherapies have revolutionized the treatment of hepatocellular carcinoma (HCC). However, the frequent emergence of treatment resistance significantly limits the clinical efficacy of HCC immunotherapy. The molecular mechanisms underlying therapy resistance remain poorly understood. Methods: To delineate the immune impact of nuclear factor erythroid 2-related factor 2 (Nrf2) inhibition, we integrated allograft tumor models with bulk and single-cell RNA sequencing analyses. Biochemical assays were performed to investigate the mechanisms underlying Nrf2 inhibition in immune resistance. The combined activity of Nrf2 inhibition with anti-programmed death-1 (PD-1) antibody and CAR-T cell therapy was also explored in vivo. Results: We show that brusatol (BRU), a specific inhibitor of Nrf2, an emerging regulator of the tumor immune microenvironment, potentiates antitumor immunity in HCC mouse models. Mechanistically, inhibition of Nrf2 downregulates surface programmed death ligand-1 (PD-L1) expression via transcriptional repression in tumor cells, while upregulating major histocompatibility complex (MHC)-I expression via nuclear factor kappa-light-chain-enhancer of activated B cells activation. Inhibition of Nrf2 in tumor cells enhances the activation of immune-related signaling pathways and promotes CD8 + T-cell infiltration into tumor tissues. Furthermore, inhibition of Nrf2 with BRU significantly enhances the efficacy of PD-1 antibody and CAR-T cells against HCC in vivo, indicating that therapeutic targeting of Nrf2 in HCC cells sensitizes them to ICIs and CAR-T immunotherapies. Conclusions: Our findings offer a novel strategy to enhance HCC immunotherapy by blocking Nrf2, which has the potential to address the low response rates observed with current HCC immunotherapies.Keywords
Funding Information
- Fundo para o Desenvolvimento das Ciências e da Tecnologia (0069/2025/AFJ)
- National Key Research and Development Program of China (2023YFA0914900)
- Science, Technology and Innovation Commission of Shenzhen Municipality (SGDX20220530111004031)
- National Natural Science Foundation of China (32570840)
- Faculdade de Ciências da Saúde, Universidade de Macau (MYRG-GRG-2025-0067-FHS)
- Faculdade de Ciências da Saúde, Universidade de Macau (SHMDF-VSEP/2024/002)
This publication has 72 references indexed in Scilit:
- NRF2 mutation enhances the immune escape of hepatocellular carcinoma by reducing STING activationBiochemical and Biophysical Research Communications, 2024
- KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistanceCell Reports, 2023
- Immune checkpoint inhibitor resistance in hepatocellular carcinomaCancer Letters, 2022
- Novel NRF2‐activated cancer treatments utilizing synthetic lethalityIUBMB Life, 2022
- Folate-mediated targeted PLK1 inhibition therapy for ovarian cancer: A comparative study of molecular inhibitors and siRNA therapeuticsActa Biomaterialia, 2022
- Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancerCancer Letters, 2021
- NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune ControlCell, 2018
- The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancerMolecular Carcinogenesis, 2017
- Brusatol overcomes chemoresistance through inhibition of protein translationMolecular Carcinogenesis, 2016
- Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugsFree Radical Biology and Medicine, 2011